Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Trulieve Cannabis
TRUL
Trulieve Cannabis
Legalization And Wellness Integration Will Fuel Cannabis Industry Transformation
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
06 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
CA$27.15
59.4% undervalued
intrinsic discount
21 Aug
CA$11.03
Loading
1Y
-14.8%
7D
6.0%
Author's Valuation
CA$27.1
59.4% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
CA$27.1
59.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-458m
1b
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$1.2b
Earnings US$8.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
2.39%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.30%
Calculation
US$8.17m
Earnings '28
x
564.07x
PE Ratio '28
=
US$4.61b
Market Cap '28
US$4.61b
Market Cap '28
/
196.98m
No. shares '28
=
US$23.38
Share Price '28
US$23.38
Share Price '28
Discounted to 2025 @ 6.30% p.a.
=
US$19.47
Fair Value '25
US$19.47
Fair Value '25
Converted to CAD @ 1.3877 USD/CAD Exchange Rate
=
CA$27.02
Fair Value '25